- Home
- PMTS vs IMMP Comparison
PMTS vs IMMP Comparison
Compare PMTS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- IMMP
- Stock Information
- Founded
- PMTS 2007
- IMMP 1987
- Country
- PMTS United States
- IMMP Australia
- Employees
- PMTS N/A
- IMMP N/A
- Industry
- PMTS Finance Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- IMMP Health Care
- Exchange
- PMTS Nasdaq
- IMMP Nasdaq
- Market Cap
- PMTS 316.9M
- IMMP 304.0M
- IPO Year
- PMTS 2015
- IMMP N/A
- Fundamental
- Price
- PMTS $28.62
- IMMP $1.78
- Analyst Decision
- PMTS Strong Buy
- IMMP Buy
- Analyst Count
- PMTS 5
- IMMP 2
- Target Price
- PMTS $34.40
- IMMP $8.50
- AVG Volume (30 Days)
- PMTS 34.9K
- IMMP 81.1K
- Earning Date
- PMTS 03-04-2025
- IMMP 03-25-2025
- Dividend Yield
- PMTS N/A
- IMMP N/A
- EPS Growth
- PMTS N/A
- IMMP N/A
- EPS
- PMTS 1.64
- IMMP N/A
- Revenue
- PMTS $480,601,000.00
- IMMP $3,019,249.00
- Revenue This Year
- PMTS $8.62
- IMMP N/A
- Revenue Next Year
- PMTS $7.15
- IMMP $20.28
- P/E Ratio
- PMTS $17.34
- IMMP N/A
- Revenue Growth
- PMTS 8.11
- IMMP 24.11
- 52 Week Low
- PMTS $15.21
- IMMP $1.65
- 52 Week High
- PMTS $35.19
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PMTS 44.09
- IMMP 41.69
- Support Level
- PMTS $27.15
- IMMP $1.65
- Resistance Level
- PMTS $31.85
- IMMP $1.88
- Average True Range (ATR)
- PMTS 1.99
- IMMP 0.10
- MACD
- PMTS -0.31
- IMMP -0.01
- Stochastic Oscillator
- PMTS 20.69
- IMMP 41.94
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.